Advanced search
Publication Cover
Modern Rheumatology Volume 23, 2013 - Issue 2
Journal homepage
129
Views
14
CrossRef citations to date
0
Altmetric
Original Article

Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs

Masayoshi HarigaiThe Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology, 1-1-24 Toranomon, Minato-ku, Tokyo 105-0001, Japan;Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan;Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo-ku,Tokyo, JapanCorrespondence[email protected]
,
Akito TakamuraThe Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology, 1-1-24 Toranomon, Minato-ku, Tokyo 105-0001, Japan;Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo-ku,Tokyo, Japan
,
Tatsuya AtsumiThe Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology, 1-1-24 Toranomon, Minato-ku, Tokyo 105-0001, Japan;Department of Internal Medicine II, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan
,
Makoto DohiThe Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology, 1-1-24 Toranomon, Minato-ku, Tokyo 105-0001, Japan;Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
,
Shintaro HirataThe Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology, 1-1-24 Toranomon, Minato-ku, Tokyo 105-0001, Japan;The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Japan, Kitakyushu, Fukuoka, Japan
,
Hideto KamedaThe Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology, 1-1-24 Toranomon, Minato-ku, Tokyo 105-0001, Japan;Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Keio University, Tokyo, Japan
,
Hayato NagasawaThe Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology, 1-1-24 Toranomon, Minato-ku, Tokyo 105-0001, Japan;Department of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
,
Yohei SetoThe Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology, 1-1-24 Toranomon, Minato-ku, Tokyo 105-0001, Japan;Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
,
Takao KoikeSapporo Medical Center NTT EC, Chuo-ku, Sapporo, Hokkaido, Japan;Global Center of Excellence Program, International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo Medical and Dental University, Tokyo, Japan
&
Nobuyuki MiyasakaThe Ad Hoc Committee for the Safety of Biological DMARDs, Japan College of Rheumatology, 1-1-24 Toranomon, Minato-ku, Tokyo 105-0001, Japan;Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo-ku,Tokyo, Japan
 show all
Pages 284-296 | Received 16 Jan 2012, Accepted 19 Apr 2012, Published online: 02 Jan 2014

REFERENCES

  • Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infiiximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.
  • Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36:898–906.
  • Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, et al. Pneumocystis jiroveci pneumonia in patients withrheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009;61:305–12.
  • Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357: 1874–6.
  • Stahel RA, Gilks WR, Lehmann HP, Schenker T. Third Inter-national Workshop on Lung Tumor and Differentiation Antigens: overview of the results of the central data analysis. Int J Cancer Suppl. 1994;8:6–26.
  • Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989;96: 68–73.
  • Ishizaka A, Matsuda T, Albertine KH, Koh H, Tasaka S, Hase-gawa N, et al. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol. 2004;286: L1088–94.
  • Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993;148:637–42.
  • Oyama T, Kohno N, Yokoyama A, Hirasawa Y, Hiwada K, Oyama H, et al. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin. Lung. 1997;175:379–85.
  • Hamada H, Kohno N, Yokoyama A, Hirasawa Y, Hiwada K, Sakatani M, et al. KL-6 as a serologic indicator of Pneumocystis carinii pneumonia in immunocompromised hosts. Intern Med. 1998;37:307–10.
  • Kohno N. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest. 1999;46: 151–8.
  • Sato H, Callister ME, Mumby S, Quinlan GJ, Welsh KI, duBois RM, et al. KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur Respir J. 2004;23:142–5.
  • Kondo T, Hattori N, Ishikawa N, Murai H, Haruta Y, Hirohashi N, et al. KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrome. Respir Res. 2011;12:32.
  • Nakajima H, Harigai M, Hara M, Hakoda M, Tokuda H, Sakai F, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol. 2000;27: 1164–70.
  • Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to inf-liximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol. 2009;19: 478–87.
  • Koiwa M, Goto S, Takenouchi K, Takahasi K, Kamada T, Nakamura H. Elevation of serum KL-6 levels in 3 patients with rheumatoid arthritis treated with adalimumab. Mod Rheumatol. 2012;22:147–51.
  • Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab in combination with metho-trexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis. 2012;71: 817–824.
  • Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab, a human anti-TNFalpha monoclonal antibody administered subcutaneously every four weeks in patients active rheumatoid arthritis despite methotrexate therapy: 24-week results of clinical and radiographic assess-ments. Arthritis Rheum. 2010;62:5757.
  • Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, et al. Pulmonary surfactant protein D in sera and bronchoal-veolar lavage fluids. Am J Respir Crit Care Med. 1995;152: 1860–6.
  • Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2010;6: 644–52.
  • Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, et al. Serum indicators for the diagnosis of pneu-mocystis pneumonia. Chest. 2007;131:1173–80.
  • Takamura A, Hirata S, Nagasawa H, Kameda H, Seto Y, Atsumi T, et al. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients-a report from the ad-hoc com-mittee for safety of biological DMARDs of the Japan College of Rheumatology. Mod Rheumatol. 2012.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.